Posted on 04/05/2020 12:47:03 AM PDT by cba123
Decades old malaria-drug Hydroxychloroquine appears to have some good results in the treatment of coronavirus patients, US president Donald Trump has said.
"We continue to study the effectiveness of Hydroxychloroquine and other therapies in the treatment and prevention of the virus and will keep the American people fully informed in our findings," Trump told reporters during a press briefing at the White House on Friday. Trump said that it looked as if Hydroxychloroquine is having some good results.
"It's looking like it (Hydroxychloroquine) is having some good results. I hope that would be a phenomenal thing, Trump said, days after the US Federal and Drug Administration approved the drug being used in the treatment of coronavirus (COVID-19) patients.
The Trump administration has stockpiled millions of doses of Hydroxychloroquine, given the urgency of the situation."We have a tremendous supply of it, we ordered in the case that it works and it's going to have some pretty big impacts. We'll see what happens, Trump said.
(Please see link for full article)
(Excerpt) Read more at m.businesstoday.in ...
Fauci will be sad. He wants to be some kind of saviour in all this...but what it comes down to is....people are just a number to Fauci.
For what it’s worth, Fauci means “jaws” in Italian.
*
Is it possible to post a transcript of this for those who desire a written item?
Excerpts:
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study Running title: Hydroxychloroquine-Azithromycin and COVID-19
Abstract We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year-old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5.
This allowed patients to rapidly de discharge from highly contagious wards with a mean length of stay of five days. We believe other teams should urgently evaluate this cost-effective therapeutic strategy, to both avoid the spread of the disease and treat patients as soon as possible before severe respiratory irreversible complications take hold
Three in vitro studies have demonstrated that chloroquine phosphate inhibits SARS-CoV-2 (8;9) and two have demonstrated that hydroxychloroquine sulfate inhibits SARS-CoV-2 (8-10).
Other studies have pointed out that drug repurposing may identify approved drugs that could be useful for the treatment of this disease including, notably, chloroquine, hydroxychloroquine and azithromycin, as well as anti-diabetics such as metformin, angiotensin receptor inhibitors such as sartans, or statins such as simvastatin (11).
In addition, chloroquine has demonstrated its efficacy in Chinese COVID-19 patients in clinical trials by reducing fever, improving CT imaging, and delaying disease progression (12-14), leading Chinese experts to recommend chloroquine-based treatment (500 mg twice per day for ten days) as a first line-treatment for mild, moderate and severe cases of COVID-19 (15).
. . .COVID treatment Patients with no contraindications (Supplementary document 1) were offered a combination of 200 mg of oral hydroxychloroquine sulfate, three times per day for ten days combined with azithromycin (500mg on D1 followed by 250mg per day for the next four days).
For patients with pneumonia and NEWS score≥5, a broad spectrum antibiotic (ceftriaxone) was added to hydroxychloroquine and azithromycin. Twelve-lead electrocardiograms (ECG) were performed on each patient before treatment and two days after treatment began. All ECGs were reviewed by senior cardiologists. The treatment was either not started or discontinued when the QTc (Bazett’s formula) was > 500 ms and the risk-benefit ratio was estimated to be between 460 and 500 ms. The treatment was not started when the ECG showed patterns suggesting a channelopathy and the risk-benefit ratio was discussed when it showed other significant abnormalities (i.e., pathological Q waves, left ventricular hypertrophy, left bundle branch block). In addition, any drug potentially prolonging the QT interval was discontinued during treatment.
Symptomatic treatments, including oxygen, were added when needed. An ionogram and verification of serum potassium levels in particular, was systematically performed upon admission. When needed, standard blood chemistry was checked.
ResultsDemographics and patient status at admission (Tables 1 and 2) A total of 80 patients with confirmed COVID-19 were hospitalised at the Méditerranée Infection University Hospital Institute (N=77) and at a temporary COVID-19 unit (N=3) with dates of entry from 3–21 March 2020.
All patients who received treatment with hydroxychloroquine and azithromycin (16) for at least three days and who were followed-up for at least six days were included in this analysis. The median age of patients was 52 years (ranging from 18 to 88 years) with a M/F sex ratio of 1.1. 57.5% of these patients had at least one chronic condition known to be a risk factor for the severe form of COVID-19 with hypertension, diabetes and chronic respiratory disease being the most frequent.
The time between the onset of symptoms and hospitalisation was on average five days, with the longest time being 17 days. 53.8% of patients presented with LRTI symptoms and 41.2% with URTI symptoms. Only 15% of patients were febrile. Four patients were asymptomatic carriers. The majority of patients had a low NEWS score (92%) and 53.8% of patients had LDCT compatible with pneumonia. The mean PCR Ct value was 23.4.
Hydroxychloroquine and azithromycin combined treatment (Table 2 and 3) The mean time between the onset of symptoms and the initiation of treatment was 4.9 days and most patients were treated on the day of admission or on the day after (93.7%). A total of 79/80 patients received treatment on a daily basis throughout the whole study period, which lasted a maximum of ten days. In one patient, the treatment had to be stopped on Day4 because, although it was well tolerated there was a potential risk of interaction with another drug. Adverse events were rare and minor.Clinical course (Table 3)
The majority (65/80, 81.3%) of patients had favourable outcome and were discharged from our unit at the time of writing with low NEWS scores (61/65, 93.8%). Only 15% required oxygen therapy. Three patients were transferred to the ICU, of whom two improved and were then returned to the ID ward. One 74 year-old patient was still in ICU at the time of writing. Finally, one 86 year-old patient who was not transferred to the ICU, died in the ID ward (Supplementary Table 1). Excerpt. Norski.
Thank you.
Anyone recall when this regimen was FIRST mentioned by President Trump?
SOTU address?
It is all about the bottom line, his stock portfolio
That is an odd study. They only gave them “Hydroxychloroquine and azithromycin”? No zinc oxide or any vitamins nothing?
This is a French study, possibly but not definitely one from which the Zelezny protocol was developed. It is ongoing but separate. Dr. Zelezny’s protocol in New York state adds zinc sulfate.
Zinc oxide is one of two different types of zinc tablets (another is zinc acetate) used sublingually and produced by the Life Extension Foundation (www.lef.org) among others.
There are other ongoing studies. I am interested in the other antimalarial antiparasite medication being discussed now.
I have said this in multiple other threads. In the hospital we are using Hydroxy and azithromycin and showing promising results. The zinc is not essential to treatment. Let’s keep our eye on the ball here. Zinc probably doesn’t hurt but is NOT required for successful treatment thus far in my experience
I’ve been keeping in touch with my niece who’s an RN in a New Orleans hospital. She told me the physicians there have recently begun prescribing hydroxychloroquine and
azithromycin much more often to patients. She said the combo really seems to work well in keeping people from progressing to intubation where even with the same medication, the outcomes are not good.
Does this comport with your observations?
If Hydroxychloroquine works, why not dump barrels of the stuff into our water supply?
I’m not a doctor or hydrological engineer.
Just asking...
Interesting Thank you
It doesn't make sense to me though. Given the virus grows mostly in the throat and nasal area (cooler area then the lungs.) Coating the throat once in a while can't hurt
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.